ADELPHI, Md. (AP) — Federal health advisers say Pfizer's HIV drug Selzentry should be approved for use by patients who have not already taken other drugs to combat the virus.
The Food and Drug Administration's panel of virus experts voted 10-4 in favor of the new use, despite some inconsistency in company studies of the drug.
The FDA is not required to follow the advice of its panels, though it usually does.
Selzentry is currently approved as a secondary option for HIV patients who are not responding to other antiviral drugs. New York-based Pfizer is asking the FDA to approve the drug as an initial treatment.